Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was
evaluated as a bleeding reduction strategy. However, the strategy of ticagrelor monotherapy …

BACKGROUND: Stopping aspirin within 1 month after implantation of a drug-eluting stent for
ticagrelor monotherapy has not been exclusively evaluated for patients with acute coronary …

Background Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine
diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet …

Aims The aim of this study was to determine the effect of ticagrelor monotherapy on clinically
relevant bleeding and major ischaemic events in relation to clinical presentation with and …

Background: Owing to the differential propensity for bleeding and ischemic events with
response to antiplatelet therapy, the safety and effectiveness of potent P2Y12 inhibitor …

Background Following percutaneous coronary intervention with stent placement to treat
acute coronary syndromes, international clinical guidelines generally recommend dual …

Background—Patients with acute coronary syndromes and history of stroke or transient
ischemic attack (TIA) have an increased rate of recurrent cardiac events and intracranial …

Importance The role of aspirin as part of antiplatelet regimens in acute coronary syndromes
(ACS) needs to be clarified in the context of newer potent P2Y12 antagonists. Objective To …

Background In the PLATO trial, ticagrelor was superior to clopidogrel in reducing
cardiovascular events among patients with acute coronary syndrome (ACS) at the expense …

Background Dual antiplatelet therapy (DAPT) is necessary to prevent thrombosis yet
increases bleeding after percutaneous coronary intervention (PCI) with drug-eluting stents …